Avacopan
Back to searchMolecule Structure
Scientific Name
Avacopan
Description of the Drug
Avacopan is an orally bioavailable complement 5a receptor (C5aR) antagonist for the treatment of severe anti-neutrophil cytoplasmic (auto)antibody (ANCA)-associated vasculitis.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB15011
http://www.drugbank.ca/drugs/DB15011
Brand Name(s)
Tavneos
Company Owner(s)
Chemocentryx Inc
Mechanism(s) Of Action
| Target Name | Target Type | Action Type | Target ChEMBL ID |
|---|---|---|---|
| C5a anaphylatoxin chemotactic receptor | SINGLE PROTEIN | ANTAGONIST | CHEMBL2373 |
Clinical Trial(s)
Unichem Links
| SureChEMBL | SCHEMBL2567144 |
| DrugBank | DB15011 |
| PubChem: Thomson Pharma | 104167810 |
| PubChem | 49841217 |
| Nikkaji | J3.663.585A |
| PDBe | EFD |
| ChemicalBook | CB03159875 |
| Guide to Pharmacology | 9450 |
